These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 13519058)

  • 1. [Biological toxicity determination with tissue cultures in multiple sclerosis].
    RIEDER HP
    Schweiz Arch Neurol Psychiatr; 1957; 80(1-2):347-50. PubMed ID: 13519058
    [No Abstract]   [Full Text] [Related]  

  • 2. [ON ANTIBODY DETECTION IN MULTIPLE SCLEROSIS. COMPARATIVE STUDIES IN BASEL AND BONN].
    RIEDER HP; ROSS J; RITZEL G; WUETHRICH R
    Med Exp Int J Exp Med; 1964; 11():128-32. PubMed ID: 14201707
    [No Abstract]   [Full Text] [Related]  

  • 3. [Is Cerebellar Soluble Lectin a major immunological target in multiple sclerosis?].
    Zanetta JP; Warter JM; Lehmann S; Kuchler S; Vincendon G
    Pathol Biol (Paris); 1991 Jan; 39(1):7-11. PubMed ID: 2011413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSF analysis in suspected MS: do bands aid?
    Hintzen RQ; Giovannoni G
    Neurology; 2008 Mar; 70(13 Pt 2):1059-60. PubMed ID: 18362264
    [No Abstract]   [Full Text] [Related]  

  • 5. Non-clinical tests for the diagnosis of multiple sclerosis.
    Rossini PM; Caramia M; Lavaroni F; Spadaro M; Floris R; Tanfani G; Zarola F; Traversa R; Marciani MG; Bernardi G
    Riv Neurol; 1987; 57(1):33-40. PubMed ID: 3629127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Biological toxicity determination of pathologic body fluids. II. Tissue culture trials with urine extracts of mental and nervous disease patients].
    GEORGI F; RIEDER HP
    Acta Anat (Basel); 1957; 30(1-4):286-97. PubMed ID: 13478330
    [No Abstract]   [Full Text] [Related]  

  • 7. [The pathogenesis of multiple sclerosis. Cytotoxic antibodies against myelin sheath tissue in multiple sclerosis].
    Frick E; Stickl H
    Fortschr Med; 1976 Jun; 94(17):1019-24. PubMed ID: 964856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Biologic markers in multiple sclerosis (I). Clinical correlations].
    Dapena D; Castillo J; López J; Prieto JM; Noya M
    Neurologia; 1992 Oct; 7(8):211-5. PubMed ID: 1449837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Biological determination of the toxicity of pathologic body fluids. I. Tests with body fluids of mental and neurological patients].
    RIEDER HP
    Confin Neurol; 1954; 14(2-3):65-87. PubMed ID: 13190852
    [No Abstract]   [Full Text] [Related]  

  • 10. [Neuropsychiatric disorders in multiple sclerosis].
    García-Moreno JM; Duque P; Izquierdo G
    Rev Neurol; 2001 Sep 16-30; 33(6):560-7. PubMed ID: 11727241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Experimental allergic encephalomyelitis as an animal model for multiple sclerosis].
    Lukinović-Skudar V; Taradi SK; Andreis I; Zupancić V; Taradi M
    Lijec Vjesn; 2001; 123(3-4):81-8. PubMed ID: 11488222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of multiple sclerosis--now and in future. The Danish Multiple Sclerosis Society and the Danish Multiple Sclerosis Group].
    Sellebjerg FT; Sørensen PS;
    Ugeskr Laeger; 2007 Mar; 169(12):1121. PubMed ID: 17394832
    [No Abstract]   [Full Text] [Related]  

  • 13. The contribution of cerebrospinal fluid oligoclonal bands to the early diagnosis of multiple sclerosis.
    Zipoli V; Hakiki B; Portaccio E; Lolli F; Siracusa G; Giannini M; Pantoni L; Pescini F; Sorbi S; Amato MP
    Mult Scler; 2009 Apr; 15(4):472-8. PubMed ID: 19153171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis.
    Deisenhammer F; Schellekens H; Bertolotto A
    J Neurol; 2004 Jun; 251 Suppl 2():II31-9. PubMed ID: 15264110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New approaches in research of therapy of multiple sclerosis].
    Hemmer B; Cepok S; Nessler S; Sommer N
    Med Klin (Munich); 2001 Sep; 96 Suppl 1():23-8. PubMed ID: 11603112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial: Immunologic mysteries of multiple sclerosis.
    Waksman BH
    N Engl J Med; 1974 Jul; 291(1):45-6. PubMed ID: 4832403
    [No Abstract]   [Full Text] [Related]  

  • 17. Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice.
    Costello F; Stüve O; Weber MS; Zamvil SS; Frohman E
    Curr Opin Neurol; 2007 Jun; 20(3):281-5. PubMed ID: 17495621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Role of neuroallergy in the pathogenesis of multiple sclerosis].
    Vilkov GA; Martirosian VV
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1985; 85(2):206-9. PubMed ID: 3885657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The management of pediatric multiple sclerosis.
    Yeh EA; Weinstock-Guttman B
    J Child Neurol; 2012 Nov; 27(11):1384-93. PubMed ID: 22914373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guideline for the use of beta-interferons in patients with multiple sclerosis--a South African proposal.
    Multiple Sclerosis Advisory Committee of the Neurological Association of South Africa (NASA)
    S Afr Med J; 2004 Nov; 94(11):917-21. PubMed ID: 15587456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.